RxDoctor Payments Data

Radu Butuc, MD

Internal Medicine · Albuquerque, NMNPI 1245579796

Payments from drug & device makers

$679in general payments, 2019–2025

Across 9 payments — averaging $75.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$179
  • Alpha Cognition USA, Inc.$145
  • Teva Pharmaceuticals USA, Inc.$122
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$111
  • Acadia Pharmaceuticals Inc$108
  • AbbVie$14

What the payments were for

  • Food & beverage$679100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$679 in reported general payments places this provider in the 80th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$374,786
Medicare patients
752
Services billed
3,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban216$61,492
OdefseyEmtricitab/Rilpiviri/Tenof Ala22$39,124
CaplytaLumateperone Tosylate38$31,222
XifaxanRifaximin11$12,300
XareltoRivaroxaban40$10,948
Spiriva HandihalerTiotropium Bromide19$10,382
JardianceEmpagliflozin33$9,723
JanuviaSitagliptin Phosphate34$9,485
Gabapentin395$6,841
Chlorpromazine Hcl16$6,182
Potassium Chloride163$5,522
TradjentaLinagliptin19$5,233
Breo ElliptaFluticasone/Vilanterol11$4,751
Divalproex Sodium95$4,724
CreonLipase/Protease/Amylase13$4,687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$14$4,68713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →